GSK Stock News Today (Dec. 23, 2025): Buyback Update, Director Buying, US Drug-Pricing Deal, and FDA Wins

GSK plc stock is ending 2025 with a dense cluster of catalysts—some bullish, some complicated, and all very “big pharma in an election-year policy blender.”

Early Tuesday (Dec. 23, 2025), GSK’s ADR (NYSE: GSK) traded around $48.59, essentially flat on the session. ^[1]
Behind that quiet tape, the company has been filing fresh buyback disclosures, reporting director share purchases, and navigating new US drug-pricing agreements—while continuing to stack up regulatory wins across respiratory and infectious disease.

Below is what’s driving the GSK stock narrative right now, and how the latest forecasts and analyst views frame the next leg.

What’s new for GSK stock on Dec. 23, 2025

Today’s “current” GSK story is less about a single headline and more about four threads converging at once:

Capital return + signal: a new share buyback execution update plus reported director (PDMR) share purchases. ^[2]
US pricing policy risk—partly defused: GSK says it reached an agreement with the US Administration to lower the cost of certain medicines and expand access, while also gaining tariff-related clarity. ^[3]
Pipeline de-risking: the FDA cleared Exdensur (depemokimab), a twice-yearly biologic for severe asthma—plus other regulatory momentum in vaccines and anti-infectives. ^[4]
Manufacturing reshaping: Samsung Biologics agreed to buy a US production facility from GSK for $280 million, a reminder that GSK is still actively tuning its footprint and capital allocation. ^[5]

Buyback watch: GSK reports more repurchases at ~1,808p VWAP

One of the most concrete “stock-specific” updates hitting screens is GSK’s disclosed buyback activity.

In a Form 6‑K titled “Transaction in own shares,” GSK said it purchased 232,912 ordinary shares on Dec. 19, 2025, with prices ranging from 1,798.50p to 1,818.00p and a volume-weighted average price (VWAP) of 1,807.58p. The repurchased shares will be held as treasury shares. ^[6]

The same filing adds important context for investors tracking the program’s scale:

The purchases were executed via BNP Paribas SA under a non-discretionary agreement announced Sept. 30, 2025. ^[7]
Since Sept. 30, GSK says it has repurchased 14,554,645 ordinary shares. ^[8]
After the Dec. 19 buyback, GSK reported 240,019,489 shares held in treasury and 4,075,425,537 shares in issue excluding treasury—used as the denominator for voting-rights calculations. ^[9]

Why this matters for the stock: buybacks can be simple capital return, but they can also be a signal—management and the board leaning into the idea that the equity is attractive relative to other uses of cash, or that consistent repurchases are the best “boring but effective” way to support total shareholder return while the pipeline matures.

Director dealing: GSK discloses multiple board member share purchases

Alongside the buyback, GSK also reported a burst of director and closely-associated-person share purchases in December.

In a separate Form 6‑K (Director/PDMR shareholding), GSK disclosed purchases including:

Ordinary shares bought on the London Stock Exchange (for example, Independent Non‑Executive Director Wendy Becker purchased 441 shares at £18.0909 on Dec. 19, 2025) ^[10]
ADS purchases on the NYSE (multiple directors bought ADSs at $48.5550 on Dec. 19, 2025, including Senior Independent Non‑Executive Director Charles Bancroft purchasing 1,577 ADSs) ^[11]
A purchase by a person closely associated with the Chair (Lady Susan Symonds bought 1,650 ordinary shares at £18.1046 on Dec. 22, 2025). ^[12]

Investors often treat director buying as a sentiment datapoint, not a standalone thesis. But when it appears near an active buyback program, it can reinforce the “the board is comfortable here” narrative—especially when the stock is being buffeted by policy headlines.

The policy headline: TrumpRx drug-pricing deals and what GSK actually agreed to

Drug pricing is the monster under the bed for pharma investors—and in late December, that monster is very much awake.

What the broader news says

US President Donald Trump announced new drug-pricing agreements with nine pharmaceutical companies, including GSK, centered on lowering costs and aligning prices more closely with other developed markets. The plan also includes a direct-to-consumer platform (“TrumpRx”) expected to launch in January, though reporting notes that practical details and ultimate savings are still uncertain. ^[13]

Market reaction across the sector was mixed-to-positive in the immediate aftermath—suggesting investors may be weighing pricing pressure against policy clarity and potential offsets. ^[14]

What GSK says it agreed to

In its own Dec. 19 press release, GSK framed the agreement as delivering actions requested by the Administration and focused heavily on respiratory access, including asthma and COPD:

GSK said it will lower the price of certain medicines in Medicaid and launch new products with a “more balanced pricing approach” across developed nations. ^[15]
GSK said it will make most of its inhaled respiratory portfolio (and other products) available via a direct purchasing platform offering savings up to 66%. ^[16]
GSK also referenced supply-chain support for a US strategic reserve of albuterol (salbutamol) as part of the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). ^[17]
Critically for investors modeling downside: GSK said the agreements provide clarity on the future US pricing framework and exclude GSK and ViiV from “s232 tariffs” for three years, while noting that detailed terms remain confidential. ^[18]

How to read this for the stock:
This is not a simple “good news / bad news” headline. The deal potentially pressures US pricing—but it also potentially reduces tail risk around tariffs and gives the company clearer commercial rules of the road. In 2026, analysts will likely focus on whether volume gains and tariff certainty can soften any margin impact.

FDA win: Exdensur is approved—twice-yearly dosing becomes a real commercial bet

GSK’s most investor-friendly kind of news is the kind that comes with three letters: FDA.

On Dec. 16, 2025, GSK announced the FDA approved Exdensur (depemokimab‑ulaa) as an add‑on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and pediatric patients aged 12+. GSK described Exdensur as the first and only ultra‑long‑acting biologic with twice‑yearly dosing approved for this patient group. ^[19]

GSK also highlighted Phase 3 SWIFT trial outcomes, including a 58% and 48% reduction in annualized asthma exacerbations versus placebo across SWIFT‑1 and SWIFT‑2, respectively. ^[20]

Reuters added an important nuance for the investment case: the FDA approval was for asthma, while the regulator did not approve the drug for chronic rhinosinusitis with nasal polyps (CRSwNP) at that time, and GSK said it would continue discussions with the FDA. ^[21]

Why investors care:
Respiratory is already a core GSK franchise, but Exdensur’s real strategic hook is convenience. If twice‑yearly dosing meaningfully improves adherence and physician adoption, it can reshape share dynamics against more frequently dosed biologics.

Vaccines: EU backing for broader Arexvy use could expand the addressable market

GSK’s vaccine franchise remains central to longer-term models—especially as investors try to separate “one-season demand noise” from durable positioning.

On Dec. 12, 2025, Reuters reported that an EMA panel backed expanded use of GSK’s RSV vaccine Arexvy for all adults above 18, which would pave the way for broader use if adopted. ^[22]

This kind of label expansion matters because it widens the target population, and in vaccines, population width is destiny.

Infectious disease: FDA expands options for gonorrhea treatment, including GSK’s Blujepa

Another under-the-radar but strategically meaningful area for GSK is anti-infectives.

Reuters reported that the FDA expanded use of GSK’s Blujepa as an oral treatment for gonorrhea. ^[23]
The FDA also published an announcement about approving two oral therapies for gonorrhea and noted that Blujepa was first approved in March 2025 for urinary tract infections. ^[24]

For investors, this is not usually a single-product “move the stock today” event. But it contributes to a broader theme: pipeline execution in areas with public-health urgency, which can translate into more stable, policy-resilient demand.

Portfolio management: Samsung Biologics to buy a US facility from GSK for $280 million

On Dec. 21, 2025, Reuters reported Samsung Biologics would buy its first US production facility from GSK for $280 million (Rockville, Maryland), with the deal expected to close by the end of Q1 2026. ^[25]

This matters because it’s a reminder that GSK isn’t just “pipeline, pipeline, pipeline.” It’s also actively managing its industrial footprint and capital intensity—often an underappreciated lever in big pharma valuation.

Forecasts and analyst views: where expectations sit heading into 2026

GSK’s own collected analyst consensus (through 2031)

GSK publishes an “Analyst consensus” table (compiled from covering brokerage estimates). As of Nov. 26, 2025 (the latest table shown), consensus estimates include:

2025 turnover:£32.515bn; 2026 turnover:£34.100bn ^[26]
2025 operating margin:29.8%; 2026 operating margin:30.4% ^[27]
2025 EPS:170.1p; 2026 EPS:184.1p ^[28]
2025 dividend per share:63.6p; 2026 dividend per share:66.2p ^[29]

The same consensus also breaks out segment expectations (Specialty, Vaccines, General Medicines) and includes product-level forecasts for key brands. ^[30]

Street ratings and price targets: “Hold/Neutral” is the modal view

Third-party compilations show a generally cautious consensus:

MarketBeat lists a consensus “Hold” rating for GSK’s ADR and an average 12‑month price target around $44.13 (with targets ranging from $35.25 to $53.00). ^[31]
Investing.com lists a consensus “Neutral” rating (based on 18 analysts) and an average 12‑month target near 1,863.6p (high estimate 2,570p, low 1,450p) for the London line. ^[32]

In other words: the stock has real momentum and real product catalysts—but many analysts appear to think a lot of that optimism is already priced in.

Notable broker positioning: JPMorgan stays underweight, but lifts the target

One example of that cautious stance: JPMorgan raised its GSK price target to 1,700p from 1,500p while keeping an Underweight rating, per The Fly / TipRanks reporting. ^[33]

Technical/market-structure commentary: momentum has improved

Some market-focused commentary has turned more constructive. Investor’s Business Daily noted GSK’s composite rating rose to 96 and described the ADR moving above a technical “buy zone” level. ^[34]
(Useful as a sentiment gauge, but still not a substitute for fundamentals.)

The near-term bull case vs. bear case for GSK stock

The bull case (what goes right)

Pipeline execution keeps converting into approvals (Exdensur now in-market) and label expansions (Arexvy in Europe), supporting the “new product cycle” narrative. ^[35]
Policy risk becomes quantifiable: the US pricing agreement may hurt some unit economics, but tariff certainty and direct purchasing mechanisms could stabilize demand and reduce headline volatility. ^[36]
Capital return supports total return, with buybacks continuing at scale. ^[37]

The bear case (what bites)

US pricing pressure proves larger than modeled, and offsets (volume, channel shift, tariff relief) don’t fully compensate. ^[38]
Commercial competition in asthma biologics and RSV vaccines limits peak sales despite approvals. ^[39]
Execution risk rises during leadership transition: Luke Miels is set to assume full CEO responsibilities on Jan. 1, 2026, making 2026 a critical “prove it” year. ^[40]

What to watch next

Here are the next checkpoints investors are likely to care about most:

Early 2026 commercial rollout details for Exdensur: pricing, payer coverage, physician adoption, and whether twice‑yearly dosing changes switching behavior. ^[41]
More clarity on the US pricing framework: what exactly changes in Medicaid pricing, how the direct purchasing platform scales, and how analysts adjust margin forecasts. ^[42]
CEO transition and 2031 ambition: GSK’s leadership has framed 2026 as pivotal and reiterated long-term growth ambitions (including >£40bn sales expectations by 2031). ^[43]
Continued buyback cadence and whether repurchases accelerate, slow, or hold steady into the new year. ^[44]